Zepbound label revision updates the diabetic retinopathy section

Eli Lilly's prescribing information for Zepbound (tirzepatide), last revised 8/2026, shows a change to the section on Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus, dated 08/2026 ^[1]. This section, listed under Warnings and Precautions as item 5.8, instructs prescribers to monitor patients who have a history of diabetic retinopathy for signs that the condition is getting worse ^[1]. The label does not specify what new data or wording changed within that section, only that the section itself was revised as of that date ^[1].

The same label update log confirms that a warning about Suicidal Behavior and Ideation was removed from the prescribing information in 02/2026 ^[1]. The label lists this removal alongside other changes made earlier in the year, including a revision to Dosage and Administration in 01/2026, an update to the Severe Gastrointestinal Adverse Reactions warning in 02/2026, and a new instruction added in 01/2026 that a Zepbound KwikPen should never be shared between patients, even if the needle is changed ^[1].

Other parts of the label remain unchanged in this revision. Zepbound still carries a boxed warning about thyroid C-cell tumors seen in rats, with a note that it is not known whether tirzepatide causes these tumors, including medullary thyroid carcinoma, in humans ^[1]. The drug remains contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1]. The label also keeps its long-standing instruction for females of reproductive potential who use oral hormonal contraceptives: switch to a non-oral method, or add a barrier method, for four weeks after starting Zepbound and for four weeks after each dose increase, because the drug delays stomach emptying and could affect how oral medications are absorbed ^[1].

Why it matters for patients

For people with type 2 diabetes who also have a history of diabetic retinopathy, the label continues to call for monitoring for progression of that eye disease while on Zepbound ^[1]. The source available does not explain what specifically changed in the wording of this section in August 2026, so patients and clinicians relying on the label should check the full prescribing information directly for the updated text, since only the date of revision is confirmed here ^[1].

The confirmed removal of the suicidal behavior and ideation warning, which happened in February 2026, means that warning no longer appears as a distinct item in the current label ^[1]. The source does not give the reasoning behind that removal or what data prompted it, so it is not yet known from these materials why Lilly took that action.

The contraception instruction is unchanged and remains relevant for anyone using oral birth control pills who starts or adjusts a Zepbound dose. The label's guidance to switch to a non-oral method, or add a barrier method for four weeks around dose changes, reflects concern that delayed gastric emptying from the drug could reduce how well an oral contraceptive is absorbed ^[1].

What happens next

The label revision took effect as of 8/2026, and the prescribing information is dated to that revision ^[1]. The source provided does not include a schedule for further updates or indicate whether additional changes to the retinopathy section or other parts of the label are expected. Patients with questions about how these label changes apply to their own treatment can review the full prescribing information or ask their prescriber, since the summary here reflects only what is stated in the official label documentation ^[1].